Hanmi Science Co., Ltd.

Ling Ai Shen

Se Chang Kwon

Sung Youb Jung

Young Jin Park

Myung Hyun Jang

Young Kyung Park

Jong Soo Lee

Dae Jin Kim

In Young Choi

Young Eun Woo

The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.

Long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity

Growing community of inventors

Seoul, South Korea

Ling Ai Shen